Shares of Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) traded up 7.3% during trading on Monday . The stock traded as high as $32.75 and last traded at $32.63, with a volume of 508,843 shares trading hands. The stock had previously closed at $30.40.

Several analysts have recently commented on the company. Jefferies Group reissued a “buy” rating on shares of Alder BioPharmaceuticals in a report on Tuesday. Zacks Investment Research cut Alder BioPharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, July 29th. Finally, Brean Capital reissued a “positive” rating and issued a $45.00 price target on shares of Alder BioPharmaceuticals in a report on Wednesday, July 27th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Alder BioPharmaceuticals has a consensus rating of “Buy” and an average target price of $44.00.

The stock has a 50-day moving average of $29.02 and a 200 day moving average of $25.72. The stock’s market capitalization is $1.80 billion.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its earnings results on Tuesday, July 26th. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by $0.04. During the same period in the previous year, the firm posted ($0.46) EPS. The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $1.14 million. The business’s revenue for the quarter was up 112900.0% compared to the same quarter last year. Equities analysts predict that Alder BioPharmaceuticals Inc. will post ($2.76) EPS for the current year.

In other Alder BioPharmaceuticals news, VP Jeffrey T. L. Smith sold 3,000 shares of the firm’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $31.17, for a total transaction of $93,510.00. Following the completion of the transaction, the vice president now owns 3,000 shares in the company, valued at $93,510. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Mark James Litton sold 6,000 shares of the firm’s stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $28.94, for a total transaction of $173,640.00. Following the transaction, the insider now owns 74,567 shares of the company’s stock, valued at approximately $2,157,968.98. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Alder BioPharmaceuticals stock. California Public Employees Retirement System raised its position in Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) by 834.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 81,300 shares of the biopharmaceutical company’s stock after buying an additional 72,600 shares during the period. California Public Employees Retirement System owned 0.19% of Alder BioPharmaceuticals worth $2,685,000 at the end of the most recent reporting period.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.